All Photos(1)



Anti-phospho-Flt-1 (Tyr1213) Antibody

Upstate®, from rabbit

Vascular endothelial growth factor receptor 1 (VEGFR-1), Vascular permeability factor receptor, Tyrosine-protein kinase FRT, Fms-like tyrosine kinase

biological source


Quality Level

antibody form

affinity isolated antibody

antibody product type

primary antibodies



purified by

affinity chromatography

species reactivity

goat, bovine, sheep, mouse, rat, human




western blot: suitable



NCBI accession no.

UniProt accession no.

shipped in

wet ice

Gene Information

bovine ... Flt1(503620)
human ... FLT1(2321)
mouse ... Flt1(14254)
rat ... Flt1(54251)


Recognizes phospho-Flt-1 (Tyr1213).


KLH-conjugated, synthetic peptide containing the sequence (...VR[pY]VN...) in which [pY] corresponds to phospho-tyrosine at residue 1213 of human Flt-1. The immunizing sequence is identical in marmoset, has 14/15 identical amino acids in rat, goat, sheep, cow, and rhesus monkey and 13/15 identical amino acids in mouse.


Research Sub Category
Growth Factors & Receptors
Research Category
Anti-phospho-Flt-1 (Tyr1213) Antibody detects level of phospho-Flt-1 (Tyr1213) & has been published & validated for use in WB.


Routinely evaluated by immunoblot on recombinant Flt-1 (Catalog # 14-562) phosphorylated upon incubation with ATP

Target description

~180 kDa (66 kDa for the fragment tested in QC)

Physical form

ImmunoAffinity Purified
Immunoaffinity purified rabbit IgG in 0.1M Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium azide.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Analysis Note

Recombinant Flt-1 (Catalogue No. 14-562) phosphorylated by ATP

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany


Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage Class Code

10 - Combustible liquids



Certificate of Analysis

Enter Lot Number to search for Certificate of Analysis (COA).

Certificate of Quality

Enter Lot Number to search for Certificate of Quality (COQ).

EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
Poindessous, V; Ouaret, D; El Ouadrani, K; Battistella, A; Megalophonos, VF; Kamsu-Kom et al.
Clinical cancer research : an official journal of the American Association for Cancer Research null
Paul Mésange et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(11), 2548-2558 (2018-03-02)
Purpose: There is extensive cross-talk between VEGF- and EGFR-pathway signaling in colorectal cancer. However, combinations of VEGF- and EGFR-targeted monoclonal antibodies (mAb) show disappointing activity, in particular for patients with mutant RAS Previous results show that tyrosine kinase inhibitors (TKI)
Zheng Zhou et al.
American journal of cancer research, 5(10), 3149-3161 (2015-12-23)
Angiogenesis is central to the growth of cancers and VEGFR-1/Flt-1 plays an important role during the neovascularization under pathological conditions. We previously founded a VEGFR1 antagonistic peptide, F56, by screening the phage peptide library. We showed that DHFR-F56 chimeric protein
Chuanke Zhao et al.
Cancer science, 106(11), 1596-1606 (2015-08-25)
Angiogenesis is a prerequisite of tumor growth and metastasis and, thus, anti-angiogenesis treatment has become an important part of cancer therapy. A 15-amino acid peptide of the fibrinogen α chain, fibrinostatin, was previously found in serum samples of gastric cancer
Weihua Guan et al.
PloS one, 6(9), e24551-e24551 (2011-09-14)
We identified that the angiotensin receptor antagonist, candesartan, has profound neurovascular protective properties when administered after ischemic stroke and was associated with a proangiogenic state at least partly explained by vascular endothelial growth factor A (VEGFA). However, the spatial distribution

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service